Dynavax has completed the long road to approval for its hepatitis B vaccine Heplisav-B.
Egg-based production dampened the effects of last year's flu vaccine, a new study says. What's worse, the problem could repeat this year.
Here is some other vaccine news of note for this week.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Hoping the world's first dengue vaccine would finally ramp up this quarter? Think again. Luckily for Sanofi, its other shots are doing far better.
Merck's star HPV vaccine missed sales expectations in the third quarter as the company had to borrow from the CDC stockpile to fulfill orders.
Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.
Sanofi Pasteur has tapped Berg to learn more about biomarkers behind flu vaccine responses.
The CDC committee in charge of vaccination policy in the U.S. endorsed GlaxoSmithKline's Shingrix over the older shot, Merck's Zostavax.